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Abstract
Rat mammary carcinogenesis models have been used extensively to study breast cancer initiation, progression, prevention,
and intervention. Nevertheless, quantitative molecular data on epithelial cell differentiation in mammary glands of
untreated and carcinogen-exposed rats is limited. Here, we describe the characterization of rat mammary epithelial cells
(RMECs) by multicolor flow cytometry using antibodies against cell surface proteins CD24, CD29, CD31, CD45, CD49f, CD61,
Peanut Lectin, and Thy-1, intracellular proteins CK14, CK19, and FAK, along with phalloidin and Hoechst staining. We
identified the luminal and basal/myoepithelial populations and actively dividing RMECs. In inbred rats susceptible to
mammary carcinoma development, we quantified the changes in differentiation of the RMEC populations at 1, 2, and 4
weeks after exposure to mammary carcinogens DMBA and MNU. DMBA exposure did not alter the percentage of basal or
luminal cells, but upregulated CD49f (Integrin a6) expression and increased cell cycle activity. MNU exposure resulted in a
temporary disruption of the luminal/basal ratio and no CD49f upregulation. When comparing DMBA- or MNU-induced
mammary carcinomas, the RMEC differentiation profiles are indistinguishable. The carcinomas compared with mammary
glands from untreated rats, showed upregulation of CD29 (Integrin b1) and CD49f expression, increased FAK (focal adhesion
kinase) activation especially in the CD29hi population, and decreased CD61 (Integrin b3) expression. This study provides
quantitative insight into the protein expression phenotypes underlying RMEC differentiation. The results highlight distinct
RMEC differentiation etiologies of DMBA and MNU exposure, while the resulting carcinomas have similar RMEC
differentiation profiles. The methodology and data will enhance rat mammary carcinogenesis models in the study of the
role of epithelial cell differentiation in breast cancer.
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Introduction
The rat is a well-established model organism to study breast
cancer etiology, prevention and treatment. The chemical carcin-
ogens 7,12-dimethylbenz(a)anthracene (DMBA) or N-methyl-N-
nitrosourea (MNU) were recognized in the 1960 s and 1970 s,
respectively, to be capable of inducing rat mammary cancer [1,2]
and have become the most commonly used mammary carcino-
gens. In susceptible rat strains, such as Wistar-Furth (WF) and
Spraque-Dawley (SD), a single dose of carcinogen is capable of
rapidly inducing multiple mammary carcinomas. Rat mammary
carcinomas display many features of human adenocarcinoma of
the breast, such as histological progression [3,4] and ovarian
hormone dependence [5,6]. In the DMBA-induced rat mammary
carcinogenesis model, Russo and Russo identified the terminal end
bud (TEB) structure in the mammary epithelium to be associated
with increased proliferation along with the formation of intraduc-
tal proliferation, in-situ carcinomas, and invasive carcinomas [7].
MNU carcinogenesis has been found to be capable of generating
invasive carcinomas as well as early stage mammary lesions [8]. In
our laboratory DMBA- and MNU-induced rat mammary
carcinogenesis models are used to decipher the genetic basis of
breast cancer susceptibility. We have identified multiple loci
modulating mammary carcinoma multiplicity in rats, of which
some have been shown to affect breast cancer risk in women [9].
These highly relevant rat models allow us to explore mechanisms
through which these loci modulate breast cancer susceptibility,
however, minimal molecular data are currently available on the
cellular composition of the rat mammary epithelium and on
quantification of the changes of protein expression phenotypes
underlying rat mammary epithelial cell (RMEC) differentiation
throughout the process of chemical carcinogenesis.
The cellular composition of the mouse mammary epithelium
has been characterized in detail by multicolor flow cytometry
using antibody staining of cell surface and internal proteins on
gently digested, monodispersed mammary glands. The epithelial
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undifferentiated mammary stem cell (MaSC) that maintains itself
through self-renewal and is capable of differentiating into
committed progenitors [10,11]. These progenitors ultimately give
rise to progeny that are the mature ductal and alveolar cells, which
belong to the luminal epithelial cell lineage lining the lumen of the
mammary gland, and the basal cells surrounding the luminal
epithelium and contacting the basement membrane (reviewed in:
[12]). Luminal cells have secretory properties. In the mouse
mammary gland, luminal cells have been shown to express heat
stable antigen (HSA; CD24) and intermediate (med) levels of
Integrin b1 (CD29) and cytokeratin (CK) 19, but not CK14
(CD24+CD29med, CK19+CK14-) [11,13]. Within the luminal
population, luminal progenitor cells have been described to
express Integrin b3 (CD61) [14]. Basal cells include mature
myoepithelial cells and have contractile muscle as well as epithelial
properties. In the mouse mammary gland, these cells are typically
identified by the expression of CD24, high (hi) levels of CD29,
CK14, smooth muscle actin (SMA) but not CK19 (CD24+
CD29hi, CK14+CK19-) [11,13,15]. Although a unique molecular
marker for the MaSC has not been identified, single mammary
epithelial cells capable of repopulating a mammary-free fat pad
have been shown to be enriched in a CD24+CD29hi population of
cells expressing high levels of Integrin a6 (CD49f), and lack
expression of stem cell antigen (SCA) 1 [10,11].
In various transgenic mouse models, a role for aberrant
mammary epithelial cell differentiation in mammary carcinogen-
esis was recognized. For example, in preneoplastic mammary
glands of transgenic mice expressing the wnt-1 oncogene under
control of the Mouse Mammary Tumor Virus (MMTV) promoter,
the percentage of mammary epithelial cells highly expressing
CD29 is increased [11]. Earlier, it was shown that ablation of
Integrin b1 abolished mouse mammary tumor development [16].
Integrin b1 has been shown to affect proliferation and differen-
tiation in the luminal lineage [17] and to be essential for MaSC
repopulation ability [18]. Similarly, targeted ablation in the
mammary epithelium of focal adhesion kinase (FAK), a cytoplas-
mic tyrosine kinase and important mediator of Integrin signaling,
significantly suppresses mammary carcinoma incidence in the
mouse MMTV-PyVT model by affecting the pool of MaSC in the
untransformed mammary gland and mammary cancer stem cells
(MaCSC) in the primary tumors [19,20]. FAK is known to affect
many cellular processes, including survival, proliferation, and
differentiation (reviewed in [21]).
In this study, we used multicolor flow cytometry to annotate the
luminal and basal/myoepithelial populations of RMECs. We
quantified the protein expression phenotypes underlying these
populations in mammary glands isolated at 1, 2, and 4 weeks after
DMBA or MNU exposure as well as in carcinomas and mammary
glands from untreated age-matched control animals of a highly
susceptible congenic recombinant inbred rat line. Following
exposure of the rats to the mammary carcinogens DMBA or
MNU, the RMECs showed a distinct cellular differentiation
etiology, while the carcinomas resulting from DMBA- or MNU-
induced carcinogenesis have a very similar cellular differentiation
profile.
Results
Characterization of RMEC populations
We optimized a protocol to obtain single cells from rat
mammary glands and frank mammary carcinomas. After the
gentle digestion procedure, each mammary gland sample yielded
approximately 8 million mononucleated cells that were aliquoted
for antibody staining and multicolor flow cytometric analysis. In
the analysis of the flow cytometric profiles, single cells were
discriminated from sticking cells based on forward scatter and side
scatter width. The live cells were gated using propidium iodide dye
exclusion (PI-negative; Fig. 1A). The rat mammary epithelial cells
(RMECs) were separated from hematopoietic and endothelial cells
based on lack of CD45 and CD31 expression, respectively
(Fig. 1A). The majority (71.468.2%) of CD45-CD31- cells
expressed CD61 (Fig. 1A), but CD61 expression does not
segregate a population. Based on expression of CD24 and
CD29, the RMECs could be divided into two distinct major
populations which showed CD24+CD29hi or CD24+CD29med
phenotypes (Fig. 1A). Intracellular staining with CK14 and CK19
identified basal cells (CK14+CK19-) in the CD24+CD29hi
population and luminal cells (CK19+CK14-) in the CD24+
CD29med population (Fig. 1B). SMA expression as evinced from
phalloidin staining identified myoepithelial cells the in CD24+
CD29hi population (Fig. 1B). Based on these parameters, CD24+
CD29med cells were identified as luminal and CD24+CD29hi
cells as basal (including myoepithelial) RMECs.
In the past, RMEC populations with differential clonogenic
capabilities were identified using PNL and anti-Thy-1 staining
[22]. In our experiments, PNL and anti-Thy-1 yielded good
separation of RMEC populations (Fig. 1C). Approximately 10% of
the RMECs was found to be PNL+Thy-1-, approximately 18%
was PNL-Thy-1+, approximately 3% was PNL+Thy-1+, and the
vast majority of the RMECs did not stain with PNL or anti-Thy-1
(Fig. 1C). The PNL+ population was found to overlap with the
CD29med population, while the Thy-1+ population overlapped
equally between the CD29med and CD29hi populations (Fig. 1C).
CD49f expression is upregulated in actively dividing cells
We evaluated the location of actively dividing RMECs on the
luminal/basal (as defined by CD24 and CD29 expression) flow
cytometric profile. Actively dividing cells (in S/G2+M phase of the
cell cycle) were identified based on more than 2n cellular DNA
content using Hoechst staining (Fig. 2A). These cells appear to be
located in the ‘upper right‘ quadrant of the luminal/basal profile,
expressing highest levels of CD24 and CD29 (Fig. 2A). Using a
gating strategy to quantify this observation, the CD24hiCD29hi
gate was strongly enriched (,300%) in actively dividing cells, as
compared with total RMECs (Fig. 2B). Besides expressing high
levels of CD24 and CD29, the actively dividing cells also expressed
elevated CD49f levels as compared with total RMECs (Fig. 2C).
Accordingly, CD49f+ cells were found to contain a higher
percentage of CD24hiCD29hi-gated cells as compared with total
RMECs (Fig. 2D).
RMEC differentiation and proliferation following DMBA
or MNU treatment
Following the characterization of the RMECs in untreated
control rats, we treated female rats with the mammary carcinogens
DMBA or MNU and quantified the protein expression phenotypes
underlying the RMEC populations at 1, 2, or 4 weeks after
treatment. Administration of DMBA to the rats did not
significantly alter the percentage of luminal and basal cells as
compared with the untreated control rats at any time point
measured (Fig. 3A). On the other hand, MNU administration
significantly altered the percentages of basal and luminal cells at 1
week after treatment (Fig. 3A). At 2 and 4 weeks after treatment,
the percentages of basal and luminal cells from the MNU-treated
rats were at similar levels compared to those from the untreated
control rats (Fig. 3A).
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luminal cells 1 and 2 weeks after DMBA treatment (Fig. 3B).
CD49f expression remained high on the basal cells from DMBA-
treated animals 4 weeks after treatment, but in luminal cells
CD49f expression returned to similar levels compared to untreated
control rats at this same time point (Fig. 3B). MNU treatment had
no effect on CD49f expression in the RMECs at any time point
studied (data not shown).
Along with the CD49f upregulation, a significantly higher
percentage of actively dividing cells was seen in luminal as well as
basal RMECs from DMBA-treated rats as compared to untreated
control rats at 1 week after treatment (Fig. 3C). At 2 weeks after
DMBA treatment, only the basal but not the luminal cells showed
a significantly higher percentage of actively dividing cells in the
DMBA-treated rats as compared with the untreated control rats
(Fig. 3C). At 4 weeks of age, there was no difference in the
percentage of actively dividing cells between the (luminal as well as
basal) RMECs from DMBA-treated rats compared to untreated
control rats (Fig. 3C). At all time points, there was a higher
percentage of luminal cells in the S/G2+M phase of the cell cycle
as compared to basal cells (Fig. 3C).
RMEC differentation in chemically induced mammary
carcinomas
We also evaluated the protein expression profile of the RMECs
from carcinomas and mammary glands from untreated control
rats of the same age (15 weeks after carcinogen exposure). The
RMECs from DMBA- or MNU-induced carcinomas appear to be
highly similar to each other in regard to their cellular
differentiation profile, but were different from the RMECs from
the mammary gland of the untreated control animals (Fig. 4A).
The RMECs from carcinomas have higher percentages of cells in
Figure 1. Characterization of rat mammary epithelial cells (RMECs) based on cell surface and intracellular markers. (A) Representative
flow cytometric histograms and dot plots showing gating for propidium iodide (PI)-negative (live) cells (left panel); exclusion of endothelial cells and
leukocytes based on CD31 and CD45 expression, respectively (middle left panel); CD61 expression in CD45–CD31– RMECs (middle right panel); CD24
and CD29 expression in CD45–CD31– RMECs identifies two major populations indicated with a red or blue circle (right panel). (B) Dot plots of
intracellular cytokeratin (CK) 14 and CK19 expression in CD45–CD31– RMECs (upper left panel); intracellular smooth muscle actin (SMA) staining with
phalloidin and CD29 expression in CD45–CD31– RMECs (upper right panel); overlay of dot plots showing CD24 and CD29 expression in CK14+CK19-
cells and CK19+CK14- cells (lower left panel); overlay of dot plots of phalloidin bright cells on CD24 and CD29 expression in CD45–CD31– RMECs
(lower right panel). Based on CK14, CK19, and SMA expression, the luminal (red) and basal (blue) populations in CD45–CD31– RMECs are identified.
(C) Contour plot showing binding of Peanut Lectin (PNL) or anti-Thy-1 in CD45–CD31– RMECs (left panel), overlaid histograms showing CD29
expression on PNL+Thy1-, PNL-Thy-1+ cells (middle left panel), contour plots showing anti-Thy-1 (middle right panel) or PNL binding in CD29med or
CD29hi cells (right panel). For all panels, rats of 12 weeks of age were used.
doi:10.1371/journal.pone.0026145.g001
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mammary gland of the control rats (Fig. 4A). The percentage of
actively dividing cells was also increased in the RMECs from
carcinomas as compared to the RMECs from the mammary gland
of the control rats (Fig. 4B). In addition, the RMECs from
carcinomas showed increased expression of CD29 and CD49f,
along with a decreased expression of CD61 (Fig. 4C). Finally, the
percentage of myoepithelial cells that stained brightly with
phalloidin, as well as Thy-1 expression were decreased in the
RMECs from carcinomas as compared to those of the mammary
gland of untreated control rats (data not shown).
Focal adhesion kinase (FAK) has been shown to signal
downstream of Integrins [23,24]. As Integrins a6 (CD49f) and
b1 (CD29) were upregulated and Integrin b3 (CD61) was
downregulated in the RMECs from carcinomas, we checked if
FAK and Y397-phosphorylated FAK (pFAK) levels were affected
in the RMECs from carcinomas. In the mammary gland from
untreated control rats, the majority of the RMECs expressed
intracellular FAK (Fig. 4D) and a smaller portion of the cells
expressed the phosphorylated form of FAK (Fig. 4E). Both FAK
and pFAK levels appear higher in the CD29med population as
compared with the CD29hi population. The expression of FAK
was specifically upregulated in CD29hi RMECs from carcinomas
as compared to CD29hi RMECs from the mammary gland of
untreated control rats (Fig. 4D), which was even more pronounced
for pFAK (Fig. 4E).
Discussion
Rat chemical carcinogenesis models for breast cancer have been
used extensively in preclinical research. The human breast and rat
mammary gland have a similar ductal-lobular organization and
mammary cancers induced in the rat are predominantly hormone-
dependent and of ductal origin, similar to the majority of human
breast cancers [3,7]. The two most widely used mammary
carcinogens are the polycyclic hydrocarbon 7,12-dimethylben-
z(a)anthracene (DMBA) and the directly alkylating agent N-
methyl-N-nitrosourea (MNU). DMBA, unlike MNU, requires
metabolic activation to become mutagenic [25]. In this study, we
first characterized the cellular differentiation profile of the rat
mammary epithelial cells (RMECs). Subsequently, we focused on
quantifying the changes of RMEC differentiation in the mammary
gland following exposure to DMBA or MNU and in the resulting
carcinomas as compared with mammary glands from untreated
control animals.
Multicolor flow cytometric profiles of mammary epithelial cells
(MECs) have been described extensively in the mouse, but not in
the rat. In our study, RMECs showed features similar to those of
mice including cell surface expression of CD24 and CD29,
defining the luminal and basal populations [11]. The luminal cells
showed a CD24+CD29med phenotype and expressed intracellular
CK19. Basal cells, the other dominant population in MECs,
showed a CD24+CD29hi phenotype and expressed intracellular
CK14. A subset of the basal cells, the myoepithelial cells, showed
bright staining with phalloidin indicating smooth muscle actin
(SMA) expression. A clear difference between the rat and mouse
profiles is that the rat basal population (with respect to the rat
luminal population) appears to express higher levels of CD29 as
compared to the mouse basal population (with respect to the
mouse luminal population). Subsequently, a distinct population
enriched in mammary stem/progenitor cells that has been shown
to express higher CD29 levels than the basal cell population in
Figure 2. Features of the actively dividing cells in CD45–CD31– RMECs. (A) Flow cytometric histogram showing gating for actively dividing
cells (cells in S/G2+M phase of the cell cycle) by having .2n cellular DNA content (left panel); representative dot plot showing the actively dividing
cells overlaid on CD24 and CD29 expression in the RMECs (right panel). (B) Representative dot plot showing gating for RMECs expressing high levels
of both CD24 and CD29 (CD24hiCD29hi gate; left panel); bar graph (right panel) showing mean 6 sem percentage of cells in S/G2+M phase of the
cell cycle in total RMECs or CD24hiCD29hi-gated cells (n=24 each). A significant enrichment of actively dividing cells was detected in the
CD24hiCD29hi-gated cells (p,0.05; indicated with an asterisk). (C) Overlaid histogram showing CD49f expression in the total RMECs and actively
dividing cells (left panel); bar graph (right panel) showing mean fluorescence intensity (MFI) in artificial units (a.u.) 6 sem of CD49f in the total RMECs
and actively dividing cells (n=14 each). Significantly different MFI is indicated with an asterisk (p,0.05). (D) Representative dot plot showing CD49f
expressing cells (CD49f+) overlaid on CD24 and CD29 expression of the RMECs (left panel); bar graph showing mean 6 sem percentage of
CD24hiCD29hi-gated cells in total RMECs or the CD49f expressing population (right panel). A significant enrichment of CD24hiCD29hi-gated cells was
detected in the CD49f expressing population (p,0.05; indicated with an asterisk). For all panels, rats of 12 weeks of age were used.
doi:10.1371/journal.pone.0026145.g002
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between the mouse and rat MEC characterizations is the
expression pattern of CD49f and CD61. In the mouse high
expression of CD49f has been shown to define the basal
population and, together with high expression of CD24, define a
MaSC-enriched population [10]. CD61 expressing cells in the
mouse mammary gland, together with low expression of CD29,
define the luminal progenitor pool [14]. In the rat, expression of
both CD49f and CD61 are detectable, but do not separate
populations of RMECs, again underscoring interspecies differenc-
es in the protein expression profile of the MECs.
We followed a previously published study in the rat that used
PNL and anti-Thy-1 staining to fractionate the RMECs [22]. That
study identified the PNL+ population to be enriched in clonogenic
cells, i.e. cells capable of forming alveolar units after transplan-
tation. PNL has also been shown to stain most alveolar epithelial
cells and luminal alveolar cells [26,27]. Here, we verify that the
PNL+ and Thy-1+ populations are segregating populations of
RMECs. The PNL+ population was found highly enriched in the
CD29med population as compared to the CD29hi population,
indicating that the clonogenic PNL+ population coincides with the
luminal cells, perhaps defining a pool of alveolar progenitor cells,
which has been suggested to underlie clonogenicity of a small
fraction of the luminal cells in mice [12,14]. In contrast to the
PNL+ population, we found the non-clonogenic Thy-1+ popula-
tion to equally overlay the CD29med and CD29hi populations.
Thy-1 has previously been found to be present on and
immediately adjacent to the myoepithelial cells of the ducts and
alveoli [28]. As we found SMA expression (a marker for
myoepithelial cells) exclusively in CD29hi cells of the basal
RMEC population, we hypothesize that either a myoepithelial cell
population defined by Thy-1 can also be found in the luminal
population, or Thy-1+ cells define a population other than
myoepithelial cells, such as cells of mesenchymal origin as
suggested earlier [22,28].
In this study, we find the luminal population to have a higher
percentage of cells in S/G2+M phase of the cell cycle as compared
with the basal population. These actively dividing cells appeared to
be enriched in cells expressing high levels of both CD24 and CD29
(CD24hiCD29hi-gated cells), as compared with the total RMECs.
Interestingly, these CD24hiCD29hi-gated cells also express
elevated levels of CD49f, a marker previously associated with
the MaSC population in mice of which the majority of cells
appeared to be cycling [10]. These findings suggest that a putative
rat MaSC-like population may be located in the luminal
population, likely consisting of those luminal cells expressing the
highest levels of CD29 and CD49f.
The focus of this study was to quantify changes in the
differentiation of the RMECs 1, 2, and 4 weeks after exposure
to DMBA and MNU and changes in RMEC differentiation
comparing carcinomas to mammary gland from untreated control
rats. DMBA treatment did not modify the percentages of RMECs
in the luminal or basal populations, but MNU treatment
drastically disrupted the luminal and basal cell populations within
1 week (Fig. 5A). The MNU-induced increase in basal cells and
decrease in luminal cells was possibly corrected by homeostatic
Figure 3. Modulation of RMEC differentiation by exposure of the rats to 7,12-dimethylbenz(a)anthracene (DMBA) or N-methyl-N-
nitrosourea (MNU). (A) Mean 6 sem percentage of basal and luminal RMEC populations in age-matched untreated control, DMBA-treated, or
MNU-treated rats at 1, 2, and 4 weeks after treatment. 1 week: control n=21, DMBA n=7, MNU n=12; 2 weeks: control n=18, DMBA n=9, MNU
n=10; 4 weeks: control n=24, DMBA n=10, MNU n=12. A significantly different percentage as compared to the age-matched control group is
indicated with an asterisk (p,0.05). (B) Representative overlaid histograms (upper panels) showing upregulation of CD49f expression in basal and
luminal cells following DMBA treatment; bar graphs (lower panels) quantifying mean fluoresence intensity (MFI) in artificial units (a.u.) 6 sem of
CD49f in basal and luminal RMECs from rats 1, 2 or 4 weeks after DMBA treatment as compared to age-matched untreated control rats. 1 week:
control n=6, DMBA n=6; 2 weeks: control n=6, DMBA n=6; 4 weeks: control n=9, DMBA n=7. Significantly different MFI comparing the DMBA
group to the control group is indicated with an asterisk (p,0.05). (C) Bar graphs showing the mean 6 sem percentage of RMECs containing .2n
cellular DNA (dividing cells in S/G2+M phase of cell cycle) in age-matched untreated control or DMBA-treated rats 1, 2, and 4 weeks after treatment. A
significantly different percentage comparing the DMBA group to the control group is indicated with an asterisk (p,0.05).
doi:10.1371/journal.pone.0026145.g003
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exposed to 7,12-dimethylbenz(a)anthracene (DMBA) or N-methyl-N-nitrosourea (MNU). (A) Representative pseudo-color dot plots
showing CD24 and CD29 expression in the RMECs from the mammary gland of an age-matched (22 weeks of age) untreated control rat (upper left
panel) and a DMBA- (upper middle panel) or MNU-induced (upper right panel) carcinoma; bar graphs (lower panel) quantifying mean 6 sem
percentage cells in the CD24hiD29hi gate within the total (CD45–CD31–) RMECs. A significantly different percentage comparing carcinomas to
mammary glands is indicated with an asterisk (p,0.05). (B) Bar graphs showing the mean 6 sem percentage of RMECs containing .2n cellular DNA
(actively dividing cells in S/G2+M phase of cell cycle). Significantly different percentage comparing RMECs from carcinomas to control mammary
glands is indicated with an asterisk (p,0.05). (C) Representative overlaid histograms showing upregulation of CD29 expression (upper left panel),
upregulation of CD49f expression (upper middle panel) and downregulation of CD61 expression (upper right panel) in RMECs of a DMBA-induced or
Integrin a6 and b1 in Mammary Carcinogenesis
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of untreated control rats within four weeks after exposure. On the
other hand, DMBA treatment resulted in significant upregulation
of CD49f, which was still detectable in the basal population 4
weeks after exposure. These observations underscore the differen-
tial etiology of mammary carcinogenesis induced by DMBA and
MNU exposure. We hypothesize that DMBA, besides having a
mutagenic effect after metabolic activation, drives mammary
carcinogenesis by increasing RMEC proliferation and modulating
CD49f-related differentiation. This hypothesis is supported by a
previous observation of expansion of terminal end bud structures
in mammary glands of DMBA-treated rats [3], which are the
structures associated with high rates of proliferation [29]. A
previous gene expression analysis on mammary glands of DMBA-
treated rats also supports this hypothesis, as a number of cell cycle
related genes, such as PCNA, Igf1, Igfbp2, and Ran were found to be
upregulated as compared with mammary glands of untreated rats
[30]. MNU is likely acutely toxic to the luminal cells, which could
explain the immediate disruption of RMEC luminal/basal
homeostasis. We have previously shown killing of RMEC
clonogens directly after MNU exposure [31] and localization of
the clonogen-enriched PNL+ cell population in the luminal
population (this study), making this hypothesis plausible.
Interestingly, despite the etiological distinction of RMEC
differentiation between exposure to the carcinogens DMBA and
MNU, the RMEC protein expression profiles of the mammary
carcinomas induced by the two carcinogens look similar. It should
be noted that on the molecular genetic level several differences
between DMBA- and MNU-induced mammary carcinomas have
been reported, including subtle carcinogen-specific expression
signatures irrespective of the histological grade of the carcinomas
[32], and frequent occurrence of Ha-Ras codon-12 mutations in
MNU-induced mammary carcinomas as compared to absence of
such mutations in DMBA-induced mammary carcinomas [33].
When comparing the mammary carcinomas to the age-matched
untreated control mammary gland, the RMECs from mammary
MNU-induced carcinoma as compared to a control mammary gland; bar graphs quantifying the mean fluorescence intensity (MFI) in artificial units
(a.u.) 6 sem of CD29 (lower left panel), CD49f (lower middle panel) and CD61 (lower right panel) on RMECs from control mammary glands and
carcinomas. Significantly different MFI is indicated with an asterisk (p,0.05). (D) Representative pseudo-color dot plot showing gating for CD29 and
focal adhesion kinase (FAK) in RMECs from a control mammary gland (upper left panel), a DMBA-induced (upper middle panel) and MNU-induced
(upper right panel) carcinoma; bar graph (lower panel) quantifying mean 6 sem percentage of CD29hiFAK+ cells. A significantly different percentage
comparing carcinomas to control mammary glands is indicated with an asterisk (p,0.05). (E) Representative pseudo-color dot plot showing gating
for CD29 and Y397-phosphorylated focal adhesion kinase (pFAK) in RMECs from a control mammary gland (upper left panel), a DMBA-induced (upper
middle panel) and MNU-induced (upper right panel) carcinoma; bar graph (lower panel) quantifying mean 6 sem percentage of CD29hi pFAK+ cells.
A significantly different percentage comparing carcinomas to control mammary glands is indicated with an asterisk (p,0.05). In the entire figure 4,
age-matched untreated control mammary glands: n=16, DMBA-induced mammary carcinomas: n=10 and MNU-induced mammary carcinomas:
n=10.
doi:10.1371/journal.pone.0026145.g004
Figure 5. Epithelial cell differentiation in mammary glands and carcinomas from 7,12-dimethylbenz(a)anthracene (DMBA)-or N-
methyl-N-nitrosourea (MNU)-exposed rats. (A) Schematic representation of the modulation of RMEC differentiation 1 week after exposure of
rats to the mammary carcinogens DMBA or MNU. DMBA exposure increases CD49f expression and proliferation (not shown here). MNU exposure
disrupts the luminal and basal homeostasis. (B) Schematic representation of the changes of RMEC differentiation in carcinomas as compared to
mammary gland from untreated age-matched (22 weeks of age) control rats. Note that the RMECs from animals of 22 weeks of age have a higher
percentage of luminal cells as compared to younger animals (comparing Fig. 1A to Fig. 4A). In both panels cell surface expression of CD24, CD29,
CD49f and CD61 and intracellular expression of focal adhesion kinase (FAK) and Y397-phosphorylated FAK (pFAK) in basal, luminal and
CD24hiCD29hi-gated cells are shown.
doi:10.1371/journal.pone.0026145.g005
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a6, FAK, and pFAK (Fig. 5B), as well as decreased expression of
Integrin b3 (Fig. 5B), SMA, and Thy-1. We noticed a shift of the
RMECs of carcinomas towards the CD24hiCD29hi gate,
resembling the CD24/CD29 profile observed in premalignant
mammary glands of transgenic MMTV-Wnt1 mice [11]. In
addition, the RMECs from mammary carcinomas have a higher
percentage of cells in S/G2+M phase of the cell cycle. As the
RMECs from mammary carcinomas also express higher levels of
Integrin a6 (CD49f), which is a marker previously associated with
MaSCs [10], show increased proliferation, and show increased
pFAK expression that was also found be associated with a stem-
progenitor cell pool [20], we hypothesize that DMBA- and MNU-
induced mammary carcinomas may have an increased pool of
stem/progenitor-like cells driving tumorigenesis. In the future, the
existance of such a population, as well as its tumorigenic potential
would have to be verified in transplantation studies.
Mammary specific ablation of FAK was earlier reported to
ameliorate mammary tumor progression in mice [34] by affecting
the mammary cancer stem/progenitor cells [20]. Early work has
demonstrated that FAK autophosphorylation at Y397 is strongly
increased upon interaction with activator proteins, such as Integrin
bs, rendering pFAK in its active state (recently reviewed in [21]).
We found in the mammary gland of untreated control rats that
about 60% of the RMECs stained positive for intracellular FAK
and about 35% of RMECs stained positive for pFAK. DMBA-
and MNU-induced mammary carcinomas showed specific upre-
gulation of FAK expression and FAK autophosphorylation in
CD29hi (basal) cells. The upregulation of Integrin b1 and a6, as
well as the activation of FAK in the mammary carcinomas may
provide an important research tool for potential use of rat
carcinogenesis models for preclinical evaluation FAK- and/or
Integrin-signaling inhibitors as anticancer drugs.
The results provide detailed insights into different populations
of RMECs. Importantly, the methodology established in this
study allowed us to quantify changes in RMEC differentiation in
the process of chemical carcinogenesis with the two most
commonly used mammary carcinogens, namely DMBA and
MNU. We also noticed an effect of age on the RMEC
differentiation profile, as rats of 22 weeks of age (Fig. 4A) have
a higher percentage of luminal cells as compared with rats of 12
weeks of age (Fig. 1A; also schematically presentated in Fig. 5B).
In the future, the contribution of age to RMEC differentiation
would have to be addressed in a separate study. Detailed
knowledge of changes in RMEC differentiation after carcinogen
exposure is important to understand the cellular differentiation
states associated with genetic and/or environmentally-induced
susceptibility to breast cancer for which the rat is a widely studied
model organism.
Materials and Methods
Animals
All animal experiments were conducted at our facility under
protocol number M01353–0–07–10 approved by the University of
Wisconsin Medical School Animal Care and Use Committee. All
studies described here were conducted using susceptible congenic
recombinant inbred rat line (WF.WKy) derived from a congenic
line (Line O) that was originally developed on the Wistar-Furth
(WF) genetic background carrying selected Wistar-Kyoto (WKy)
alleles [9]. This susceptible congenic control line, WF.WKy,
harbors the WF genotype across all Mcs loci and displays the same
mammary carcinoma multiplicity phenotype as the susceptible
inbred WF strain [9]. Rats were maintained in a 12-hour light/12-
hour dark cycle and were provided with Teklad lab blox chow and
acidified water ad libitum.
DMBA/MNU treatment
At 49–57 days of age, WF.WKy female rats were administered
7,12-dimethylbenz(a)anthracene (DMBA; ACROS Organics,
Fisher Scientific) in sesame oil as a single gastric intubation of
65 mg/kg of body weight or were injected intraperitonially with
N-methyl-N-nitrosourea (MNU; Sigma) at 50 mg/kg of body
weight. DMBA or MNU treatment of the susceptible WF.WKy
rats routinely yields ,8o r,4 mammary carcinomas per rat at 15
weeks post-treatment, respectively [35]. The treated and age-
matched untreated control rats were sacrificed 1, 2, 4 or 15 weeks
after carcinogen exposure and their mammary glands or frank
mammary carcinomas were isolated.
Isolation of mammary epithelial single cells
The protocol used to isolate and monodisperse RMECs was
optimized earlier [36]. For each rat, tissue from both abdominal
and the adjacent inguinal glands with lymph nodes (LN) excised,
or frank mammary carcinomas was kept separately and finely
scissor-minced over ice. Each minced mammary gland or
mammary carcinoma sample was exposed to 10 ml or 5 ml,
respectively, of GIBCO DMEM/F12 (Invitrogen) containing
0.01 g/ml of type III Collagenase (Worthington) for 2 hours at
37uC under gentle horizontal shaking. DNAseI (Worthington) was
added to 0.2 mg/ml and the samples were incubated for 10 min
under vigorous shaking. Fat was removed from the pelleted cell
fraction by pipetting and the pellet was washed once with 10 ml of
DMEM/F12. To monodisperse, the cells were pelleted and
dissolved in 2 ml prewarmed (37uC) Hanks’ Balanced Salt
Solution (HBSS, GIBCO) containing 0.025% (w/v) of Trypsin
(Worthington), and 6.8 mM of EDTA. After 5 min of trypsin
treatment, 4 ml of DMEM/F12 containing 10% of Fetal Bovine
Serum (FBS; Hyclone) was added to stop the reaction. The cells
were spun, resuspended in 2 ml of DMEM/F12 containing 10%
FBS and passed through a 40 mm cell strainer. To rinse the
centrifugation tube, another 2 ml of DMEM/F12 with 10% FBS
was added and passed through the same cell strainer.
Antibody staining of RMEC
To stain the single cells, rat antibodies against CD49f (Santa
Cruz), CD24, CD29, CD31, CD45, CD61, and Thy-1 (BD
pharmingen) or Peanut Lectin (Sigma) were used. Antibodies
against CD24, CD31 and CD49f were not available for the rat
with the desired fluorochrome so these were conjugated in our
laboratory with amine reactive DyLight dyes (with excitation
wavelength 405 nm, 550 nm, 633 nm or 680 nm) using DyLight
Microscale labeling kits following manufacturer’s instructions
(Pierce). Freshly isolated single cells were incubated with
antibodies for 20 min on ice for surface staining, washed and
fixed in 1% paraformaldehyde. The stained samples were acquired
on a BD LSR II flow cytometer equipped with 4 lasers (multi-line
UV, 405 nm, 488 nm and 633 nm). A subset of stained and fixed
cells were permeabilized with 0.5% Tween-20 (15 min, at room
temp) followed by 0.5% Triton-X100 (5 min, at room temp) and
were stained with fluorochrome conjugated antibodies against rat
CK14 and CK19 (Abcam) or FAK (Cell Signaling Technologies)
and Alexa Fluor-532-phalloidin (Invitrogen). Cells were stained
with Hoechst33342 (10 mg/ml) for 2 hr. Hoechst fluorescence
(350 nm excitation/450 nm emission, linear scale) was used for
cellular DNA content and cell cycle analysis. Propidium iodide
was added immediately before acquiring the samples. The cells
were acquired on a BD FACS Aria flow cytometer equipped with
Integrin a6 and b1 in Mammary Carcinogenesis
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The data were collected as fcs3 files using FACS Diva software
and analyzed using FlowJo software (Treestar Inc). Data files
obtained from cell samples stained with single antibodies and
control unstained cell samples were used for compensation. Data
on percentages of cells in various gated populations or Mean
Fluorescence Intensities (MFI) of entire populations were exported
and statistically analyzed using Student’s t-test in MS Excel.
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